The market has been high on Acasti Pharma Inc (ACST) stock recently. ACST gets a Bullish score from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With ACST Stock Today?
Acasti Pharma Inc (ACST) stock has gained 11.08% while the S&P 500 is down -0.02% as of 1:10 PM on Thursday, Jan 21. ACST has gained $0.08 from the previous closing price of $0.76 on volume of 180,512,526 shares. Over the past year the S&P 500 has risen 15.96% while ACST has gained 23.53%. ACST lost -$1.25 per share in the over the last 12 months.
To see the top 5 stocks in the Biotechnology industry click here.
More About Acasti Pharma Inc
Acasti Pharma Inc is a biopharmaceutical innovator advancing a cardiovascular drug, CaPre (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. The company is focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the blood lipids associated with cardiovascular disease risk. The Company is developing CaPre in a Phase 3 clinical program in patients with severe hypertriglyceridemia.
Click Here to get the full Stock Score Report on Acasti Pharma Inc (ACST) Stock.
